Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 4 , ISSUE 2 ( July-December, 2014 ) > List of Articles


A Case of Breast Cancer Following Infliximab Treatment for Treatment-Refractory Crohn’s Disease

Vedat Goral, Belkis Unsal, Oya Nermin Sivrikoz

Citation Information : Goral V, Unsal B, Nermin Sivrikoz O. A Case of Breast Cancer Following Infliximab Treatment for Treatment-Refractory Crohn’s Disease. Euroasian J Hepatogastroenterol 2014; 4 (2):104-106.

DOI: 10.5005/jp-journals-10018-1112

License: CC BY-NC 4.0

Published Online: 01-07-2013

Copyright Statement:  Copyright © 2014; The Author(s).


Crohn’s disease is a chronic, or long lasting inflammatory disease in the gastrointestinal (GI) tract. Most commonly, Crohn’s disease affects the small intestine and the beginning of the large intestine. Treatment for Crohn’s disease usually involves drug therapy or, in certain cases, surgery. Several side effects develop from the use of drugs. A case with Crohn’s disease refractory to 5-ASA, corticosteroid and azathioprine treatments who developed breast carcinoma following infliximab treatment is being presented in this report. Case: SE, aged 44 years, presented to our polyclinic with weight loss, abdominal pain and flatulence. The patient had no response to mesalazine, steroid and azathioprine therapy. Upon identifying inflammatory stricture with abdominal MR, the medicines the patient has been using was discontinued and anti-TNF alpha (infliximab) treatment was initiated after receiving the consent of the patient. At 3rd month of treatment, the patient detected a small mass at the left breast. Mastectomy was performed and axillary lymph nodes were resected. Because breast cancer was detected following infliximab treatment in this case, we believe that a breast examination (physical examination, mammary USG) must be performed in female patients prior to infliximab therapy.

PDF Share
  1. Marchioni RM, Lichenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol 2013 May;19(17):2591-2602
  2. Tumor necrosis factor-α inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum 2013; 65(1):48-58
  3. Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. Drug Saf 2008;31(12): 1135-1144
  4. Spontaneous regression of colonic lymphoma following infliximab and azathioprine withdrawal in patients with Crohn‘s disease. Inflamm Bowel Dis 2013 Apr;19(5):E69-E70
  5. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2014 Mar;39(5):447-458
  6. Drug therapies and the risk of malignancy in Crohn‘s disease: results from the TREAT™ Registry. Am J Gastroenterol 2014 Feb;109(2):212-223
  7. Ten years of inliximab for Crohn‘s disease: outcome in 469 patients from 2 tertiary referral centers. Inflamm Bowel Dis 2013 Jul;19(8):1622-1630
  8. Breast cancer in a male with ankylosing spondylitis treated with TNF-alpha antagonists. Joint Bone Spine 2009 Jul;76(4):421-423.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.